Skip to main content

Table 2 Potential biomarkers in liver associated with AEE treatment based on UPLC-Q-TOF/MS analysis in hyperlipidemic rat

From: Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats

NO. RT VIP m/z Formula Metabolite Trend
M/C AEE/M
1 1.11 2.33 118.0866 C5H11NO2 Valine **
2 1.73 2.46 137.0459 C5H4N4O Hypoxanthine ** *
3 2.85 3.38 166.0857 C9H11NO2 Phenylalanine *
4 9.31 1.89 466.3179 C26H43NO6 Glycocholic acid **
5 12.12 2.76 524.3730 C26H54NO7P LysoPC (18:0) **
6 13.63 2.92 568.3413 C30H50NO7P LysoPC (22:6) **
7 13.81 6.30 544.3411 C28H50NO7P LysoPC (20:4) ** *
8 14.83 2.087 400.3437 C23H45NO4 Palmitoylcarnitine **
9 16.91 2.15 428.3752 C25H49NO4 Stearoylcarnitine **
10 1.74 1.85 132.1017 C6H13NO2 Isoleucine *
11 3.41 1.44 220.1178 C9H17NO5 Pantothenic acid **
12 3.93 1.52 205.0971 C11H12N2O2 Tryptophan **
13 10.32 1.82 318.301 C18H39NO3 Phytosphingosine ** **
14 11.08 1.81 450.3228 C26H43NO5 GUDCA **
15 13.35 1.36 494.3256 C24H48NO7P LysoPC (16:1) * **
16 14.04 1.41 424.3438 C25H45NO4 Linoleyl carnitine **
17 1.22 1.08 147.0767 C5H10N2O3 Glutamine **
18 1.66 1.16 613.1611 C20H32N6O12S2 Oxidized glutathione **
19 1.67 1.13 123.0554 C6H6N2O Niacinamide **
20 9.90 1.10 500.3053 C26H45NO6S TCDCA **
21 14.14 1.26 542.3231 C28H48NO7P LysoPC (20:5)
22 15.16 3.23 546.3561 C28H52NO7P LysoPC (20:3) **
23 1.75 2.10 267.0754 C10H12N4O5 Inosine ** **
24 4.68 2.20 784.1549 C27H33N9O15P2 FAD **
25 16.66 2.42 327.2352 C22H32O2 DHA *
26 16.91 3.04 303.2348 C20H32O2 Arachidonic acid *
27 1.10 1.00 195.0525 C6H12O7 Gluconic acid **
28 4.59 1.01 686.1462 C21H35N7O13P2S Dephospho-CoA **
  1. M/C: model versus control; AEE/M: AEE versus model; * P < 0.05, ** P < 0.01. GUDCA: Glycoursodeoxycholic acid; TCDCA: Taurochenodesoxycholic acid; DHA: Docosahexaenoic acid; FAD: flavine-adenine dinucleotide